Cancer
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial
By Mikkelsen SU, Al-Mousawi A, Puglisi AB and 24 others.
Abstract
Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients with clonal cytopenia of undetermined significance (CCUS) or lower risk myeloid malignancies.